Literature DB >> 29667764

RRM2 promotes the progression of human glioblastoma.

Chao Li1, Jingfang Zheng2, Si Chen1, Bin Huang1, Guosheng Li3, Zichao Feng4, Jiwei Wang4, Shujun Xu1.   

Abstract

Glioblastoma pathogenesis is related to multiple processes that affected by dozens of regulatory factors, but the potential underlying factors regulating glioblastoma progression remains unclear. The goal of this research was to determine how the ribonucleotide reductase M2 subunit (RRM2) influenced proliferation, invasion, migration, and apoptosis of human glioblastoma cells. The level of proliferation of human glioblastoma cells was measured through CCK8, colony formation assay and immunofluorescence stains. Flow cytometry (FCM), wound healing, and transwell assays were conducted to detect cell apoptosis, migration, and invasion. Apoptotic level of cells and invasion-related expression of protein were measured by Western blot. Xenograft tumor model was established to confirm effect of RRM2 on the proliferation of human glioblastoma cells in vivo. Silencing RRM2 inhibited proliferation, invasion, and migration of glioblastoma cells whereas enhanced apoptosis rate. Overexpressing RRM2 promoted proliferation, migration and invasion but suppressed apoptosis. In vivo, Overexpressing RRM2 accelerated the tumor growth in glioblastoma cells. The present study illustrated that RRM2 was overexpressed in human glioblastoma cells. RRM2 promoted proliferation, migration, and invasion but inhibited apoptosis of human glioblastoma cells.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  RRM2; apoptosis; human glioblastoma; invasion; migration; proliferation

Mesh:

Substances:

Year:  2018        PMID: 29667764     DOI: 10.1002/jcp.26529

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  15 in total

1.  MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.

Authors:  Ying Liu; Yong Zhang; Qiubo Li; Ruiqi Xu; Nian Huang
Journal:  Thorac Cancer       Date:  2022-05-22       Impact factor: 3.223

2.  LncRNA PART1 Stimulates the Development of Ovarian Cancer by Up-regulating RACGAP1 and RRM2.

Authors:  Hui Li; Yuansheng Lei; Shuangxue Li; Feng Li; Jieyun Lei
Journal:  Reprod Sci       Date:  2022-05-12       Impact factor: 2.924

3.  High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.

Authors:  Cheng-Yu Jin; Liang Du; A-Han Nuerlan; Xiao-Lei Wang; Yong-Wei Yang; Rui Guo
Journal:  Aging (Albany NY)       Date:  2020-12-19       Impact factor: 5.682

4.  Bioinformatics analysis of the circRNA-miRNA-mRNA network for non-small cell lung cancer.

Authors:  Xueying Cai; Lixuan Lin; Qiuhua Zhang; Weixin Wu; An Su
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

5.  Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib‑based therapy.

Authors:  Chunshui Liu; Yuying Li; Ruiping Hu; Wei Han; Sujun Gao
Journal:  Oncol Rep       Date:  2019-06-11       Impact factor: 3.906

6.  EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness.

Authors:  Houda Tabbal; Amandine Septier; Mickael Mathieu; Coralie Drelon; Stéphanie Rodriguez; Cyril Djari; Marie Batisse-Lignier; Igor Tauveron; Jean-Christophe Pointud; Isabelle Sahut-Barnola; Bruno Ragazzon; Guillaume Assié; Jérôme Bertherat; Anne-Marie Lefrançois-Martinez; Antoine Martinez; Pierre Val
Journal:  Br J Cancer       Date:  2019-07-31       Impact factor: 7.640

7.  LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2.

Authors:  Na Huang; Wei Guo; Ke Ren; Wancheng Li; Yi Jiang; Jian Sun; Wenjing Dai; Wei Zhao
Journal:  Front Oncol       Date:  2019-10-22       Impact factor: 6.244

8.  Identification of potential target genes and crucial pathways in small cell lung cancer based on bioinformatic strategy and human samples.

Authors:  Xiuwen Chen; Li Wang; Xiaomin Su; Sen-Yuan Luo; Xianbin Tang; Yugang Huang
Journal:  PLoS One       Date:  2020-11-13       Impact factor: 3.240

9.  RRM2 silencing suppresses malignant phenotype and enhances radiosensitivity via activating cGAS/STING signaling pathway in lung adenocarcinoma.

Authors:  Xueping Jiang; Yangyi Li; Nannan Zhang; Yanping Gao; Linzhi Han; Shuying Li; Jiali Li; Xingyu Liu; Yan Gong; Conghua Xie
Journal:  Cell Biosci       Date:  2021-04-15       Impact factor: 9.584

10.  Prognostic Prediction Model for Glioblastoma: A Metabolic Gene Signature and Independent External Validation.

Authors:  Chuxiang Lei; Wenlin Chen; Yuekun Wang; Binghao Zhao; Penghao Liu; Ziren Kong; Delin Liu; Congxin Dai; Yaning Wang; Yu Wang; Wenbin Ma
Journal:  J Cancer       Date:  2021-05-05       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.